key: cord-0828323-0ctjk7m1
authors: Demelo‐Rodriguez, Pablo; Farfán‐Sedano, Ana Isabel; Pedrajas, José María; Llamas, Pilar; Sigüenza, Patricia; Jaras, María Jesús; Quintana‐Diaz, Manuel; Fernández‐Capitán, Carmen; Bikdeli, Behnood; Jiménez, David; Monreal, Manuel
title: Bleeding risk in hospitalized patients with COVID‐19 receiving intermediate‐ or therapeutic doses of thromboprophylaxis
date: 2021-06-20
journal: J Thromb Haemost
DOI: 10.1111/jth.15400
sha: a70051919152d5cbee51c020281e684c6d85844e
doc_id: 828323
cord_uid: 0ctjk7m1

INTRODUCTION: Some local protocols suggest using intermediate or therapeutic doses of anticoagulants for thromboprophylaxis in hospitalized patients with coronavirus disease 2019 (COVID‐19). However, the incidence of bleeding, predictors of major bleeding, or the association between bleeding and mortality remain largely unknown. METHODS: We performed a cohort study of patients hospitalized for COVID‐19 that received intermediate or therapeutic doses of anticoagulants from March 25 to July 22, 2020, to identify those at increased risk for major bleeding. We used bivariate and multivariable logistic regression to explore the risk factors associated with major bleeding. RESULTS: During the study period, 1965 patients were enrolled. Of them, 1347 (69%) received intermediate‐ and 618 (31%) therapeutic‐dose anticoagulation, with a median duration of 12 days in both groups. During the hospital stay, 112 patients (5.7%) developed major bleeding and 132 (6.7%) had non‐major bleeding. The 30‐day all‐cause mortality rate for major bleeding was 45% (95% confidence interval [CI]: 36%‐54%) and for non‐major bleeding 32% (95% CI: 24%‐40%). Multivariable analysis showed increased risk for in‐hospital major bleeding associated with D‐dimer levels >10 times the upper normal range (hazard ratio [HR], 2.23; 95% CI, 1.38–3.59), ferritin levels >500 ng/ml (HR, 2.01; 95% CI, 1.02–3.95), critical illness (HR, 1.91; 95% CI, 1.14–3.18), and therapeutic‐intensity anticoagulation (HR, 1.43; 95% CI, 1.01–1.97). CONCLUSIONS: Among patients hospitalized with COVID‐19 receiving intermediate‐ or therapeutic‐intensity anticoagulation, a major bleeding event occurred in 5.7%. Use of therapeutic‐intensity anticoagulation, critical illness, and elevated D‐dimer or ferritin levels at admission were associated with increased risk for major bleeding.

The coronavirus disease of 2019 (COVID-19) is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). A number of studies found several hemostatic abnormalities, including intravascular coagulopathy, in patients infected by COVID-19. [1] [2] [3] [4] Additionally, critical illness and immobility predispose these patients to develop venous thromboembolism (VTE). [5] [6] [7] [8] [9] [10] Based on a recent systematic review and meta-analysis, the overall incidence of VTE in hospitalized patients with COVID-19 was estimated at 17% (95% confidence interval [CI]: 13.4%-20.9%), and the incidence of major bleeding was 3.9% (95% CI: 1.2-7.9). 11 Multiple ongoing randomized controlled trials are currently evaluating the role of a group of antithrombotic regimens in patients with COVID-19. In most trials, the intensity of antithrombotic therapy is proportional to the expected VTE rates.

or fully therapeutic doses of anticoagulants) are being considered in trials of hospitalized patients.

A key to understanding the net benefit from escalated-dose empiric anticoagulation is the potential risk reduction for thrombosis versus the risk of bleeding. While some research has focused on the thrombotic event rates, the true hemorrhagic event rates, predictors of major bleeding events, or the association between bleeding and mortality remain largely unknown.

The RIETE (Registro Informatizado de Enfermedad TromboEmbólica) Registry is an ongoing, multicenter, international, observational registry of consecutive patients with objectively confirmed acute VTE (ClinicalTrials.gov identifier: NCT02832245). 12 Since March 25, 2020, the Steering Committee of RIETE agreed to take advantage of the existing platform of RIETE investigators to build two new registries of hospitalized patients with COVID-19 aimed to identify those at increased risk for VTE or for bleeding.

We recently published the results of the first study, where we tried to identify patients at increased risk for VTE. The current study describes the results of a call to recruit data from hospitalized patients with COVID-19 that received higher than recommended doses of anticoagulants for VTE prophylaxis during their hospital stay. We hypothesized that in some patients the use of intermediate-or fulltherapeutic doses of anticoagulants might be associated with unacceptably high rates of bleeding. Thus, in the current study we aimed to: (1) identify hospitalized patients at increased risk for bleeding while receiving higher than recommended doses of anticoagulants for VTE prophylaxis, and (2) 

There was no intervention planned. The main goals of this prospective study were to understand the incidence of in-hospital major and clinically relevant non-major bleeding events, and to identify the This study used major bleeding as the primary endpoint, and clinically relevant non-major bleeding as secondary outcome. Major bleeding was defined as bleeding events that were overt and required a transfusion of two units or more of blood; were retroperitoneal, spinal, intracranial, intrathecal, intrapericardial, or intraocular; or were fatal. 12 This is the definition we use in the RIETE registry, and closely resembles the definition of the International Society on Thrombosis and Haemostasis. Non-major bleeding were those overt bleeds not meeting criteria for major bleeding but that required medical assistance. D-dimer assays were not centrally provided: levels were compared according to each hospital's practice. Because the different D-dimer assays may use different detection antibodies and detection methods, and often different calibrators, [13] [14] [15] we requested that participating centers provide information on the different D-dimer manufacturers, units, and normal cut-off values. Then, we compared D-dimer levels across the different centers according to how many times they exceeded the upper limit of normality in each center.

Therapeutic-dose prophylaxis included enoxaparin 1 mg/kg twice daily or 1.5 mg/kg once daily or equivalent doses of other anticoagulants including any low-molecular-weight heparin, unfractionated heparin, or direct oral anticoagulants. Intermediate-dose prophylaxis was defined as weight adjusted, double-dose prophylaxis, or any dosage greater than the standard dose and lower than the therapeutic dose.

The study reported categorical data as proportions and continuous data as mean and standard deviation (SD) or median (interquartile range [IQR]) days. We used unpaired two-tailed t-tests or the Mann-Whitney U test (for those variables found not to follow a normal distribution) for comparisons in the distributions of continuous variables, and chi-squared or Fisher's exact tests to compare the categorical data between the two groups. We compared demographics, patients' disposition status (hospitalized in a medical ward or in an ICU), blood tests, and pharmacological VTE prophylaxis according to the occurrence of bleeding complications.

Then, we performed a multivariable analysis through a logistic regression model trying to identify independent predictors for major bleeding during admission. The risk for major bleeding was evaluated using competing risk models, with mortality (not due to bleeding) as the competing risk. Covariates entering into the model were selected by a significance level of P < .10 on univariable analysis or by a well-known association reported in the literature. We built a prognostic score assigning points to each independent variable according to regression coefficients beta, rounding to the nearest integer or a multiple of it. We assigned a risk score to each patient by adding up points for each independent variable. We conducted statistical analyses using SPSS (IBM SPSS Statistics for Windows, Version 25.0: IBM Corp.). other 37), and 50 patients who bled died within the first 30 days after bleeding. Interestingly, there was a large variability in the major bleeding rates across different centers, ranging from 1.1% to 14% (Table 1) .

Patients developing major or non-major bleeding were more likely to be in the ICUs than in medical wards, and to have higher levels of D-dimer, interleukin-6, or ferritin than those that did not bleed (Table 3 ). There were no differences in mean levels of platelet count, fibrinogen, or creatinine clearance. Among patients receiving intermediate doses of anticoagulants, the rate of major bleeding was 4.4%, and non-major bleeding 5.4%. Among those receiving therapeutic doses, the rates were 8.6% and 9.5%, respectively. Both rates were higher in patients receiving therapeutic doses than in those 

On multivariable analysis, patients admitted in the ICU (HR: 1.91; 95% CI: 1.14-3.18; P = .014), those with D-dimer levels above 

Our study, obtained from a large prospective study of patients hospitalized for COVID-19 receiving higher than recommended doses of anticoagulants for VTE prophylaxis, reveals that 1 in every 18 (5.7%) suffered major bleeding, and 1 in every 15 (6.7%) had non-major bleeding. This is important because the 30-day mortality rate in patients with major bleeding (45%) was more than 2-fold higher than in those that did not bleed (18%), and major bleeding was a significant predictor of 30-day mortality, after adjusting for potential confounders. Because the use of therapeutic doses of anticoagulants was a predictor for major bleeding, early Our study also has some strengths: to our knowledge ours is the first study to identify hospitalized patients with COVID-19 at increased risk for bleeding, using a large cohort of real-life patients (without exclusion criteria) from many centers. The strengths of the current study are the large sample of patients with prospective data collection from several hospitals, and standardized a priori implemented definitions for major bleeding and non-major bleeding. A plethora of ongoing randomized trials will be elucidating the role of a number of antithrombotic regimens with different intensities.

Results of these trials should help clarify whether any of the antithrombotic regimens under investigation can safely mitigate thrombotic complications and improve patient outcomes. However, the majority of these trials excluded patients perceived to be at high risk of bleeding, such as those with a history of major bleeding, thrombocytopenia, or renal insufficiency. These patients were not excluded in our study.

In conclusion, 5.7% of hospitalized patients for COVID-19 receiving intermediate or therapeutic doses of anticoagulants for VTE prophylaxis suffered major bleeding, and 6.7% had non-major bleeding. Patients with major bleeding had a more than 2-fold higher mortality rate than those that did not bleed. Use of therapeuticintensity anticoagulation, critical illness, and D-dimer and ferritin levels at admission were associated with increased hazards of major bleeding. 

We express our gratitude to S&H Medical Science Service, for their quality control data, logistic, and administrative support and

Prof. Salvador Ortiz, Universidad Autónoma Madrid and Silvia

Galindo, both Statistical Advisors in S&H Medical Science Service for the statistical analysis of the data presented in this paper.

Dr. Bikdeli reports that he is a consulting expert, on behalf of the plaintiff, for litigation related to two specific brand models of IVC filters.

The rest of authors state no conflicts of interest regarding this article. 

Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

COVID-19 and thrombotic or thromboembolic disease: Implications for prevention antithrombotic therapy, and follow-up: JACC State-of-the-art review

COVID and coagulation: bleeding and thrombotic manifestations of SARS-CoV2 infection

High risk of thrombosis in patients in severe SARS-Co-V-2 infection: a multicenter prospective cohort study

Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients

Incidence of venous thromboembolism in hospitalized patients with COVID-19

Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia

Incidence of venous thromboembolism and bleeding among hospitalized patients with COVID-19: a systematic review and meta-analysis

Rationale, design and methodology of the computerized registry of patients with venous thromboembolism (RIETE)

International survey on d-dimer test reporting: A call for standardization

Reporting of D-dimer data in COVID-19: Some confusion and potential for misinformation

Harmonisation of D-dimer. A call for action

Safety of intermediate dose of low molecular weight heparin in COVID-19 patients

Anticoagulation and bleeding risk in patients with COVID-19

The hazard of (sub) therapeutic doses of anticoagulants in non-critically ill patients with Covid-19: The Padua province experience

Thrombotic and haemorrhagic complications in critically ill patients with COVID-19: A multicentre observational study

COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

COVID-19 and its implications for thrombosis and anticoagulation

Bleeding risk by intensity of anticoagulation in critically ill patients with COVID-19: a retrospective cohort study

Systematic testing for venous thromboembolism in hospitalized patients with COVID-19 and raised D-dimer levels

For the RIETE-BLEEDING Investigators. Bleeding risk in hospitalized patients with COVID-19 receiving intermediate-or therapeutic doses of thromboprophylaxis